Guardant Health, Inc. · NASDAQ:GH
Guardant Health — Investor Presentation (January 2019)
28 slides from Guardant Health's investor presentation, Jan 7, 2019
Slide 1: Guardant Health Investor Presentation January 2019
Guardant Health Investor Presentation January 2019
Slide 2: Safe harbor statement
Safe harbor statement This presentation contains “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. All forward-looking information is inherently uncertain and actual results may differ materially from assumptions, est
Slide 3: The mission of Guardant Health is to conquer cancer with data
The mission of Guardant Health is to conquer cancer with data Expanding precision oncology to all stages of disease through easier access to cancer’s underlying molecular information Market leading comprehensive 6,000+ 50+ 80,000+ 90%+94% liquid biopsy oncologists biopharma tests ordered GrowthReven
Slide 4: Tumors shed cell-free nucleic acids into the blood at low concentrations
Tumors shed cell-free nucleic acids into the blood at low concentrations Guardant proprietary technology unlocks these tumor signals from a simple blood draw TUMOR 4
Slide 5: Focused on expanding the scope of precision oncology
Focused on expanding the scope of precision oncology Therapy Selection Recurrence Monitoring Early Detection Late-stage cancer patients Cancer survivors Asymptomatic individuals No Tissue Available Limitations of Tissue Availability and High False Positive Rate LimitationsCurrent Exhaustion Approach
Slide 6: Realizing the $35B+ U.S. opportunity
Realizing the $35B+ U.S. opportunity requires delivering the right information for the right intervention for the right patient population U.S. Patient Advanced-Stage Cancer Cancer Survivors Asymptomatic, Hi-Risk Population ~700 K ~15 million ~35 million Screening & Early Therapy Selection Recurrenc
Slide 7: Digital sequencing platform
Digital sequencing platform Patented proprietary technology for unlocking cancer’s signals from blood G U A R D A N T D I G I TA L S E Q U E N C I N G P L AT F O R M High- Next Learning - 2 Efficiency Generation Bioinformatics - 1 Chemistry Sequencing Engine TCAGCA GTGCGCTA AGCTA TGCATG GCATCG GTGTG
Slide 8: Digital Sequencing Platform: underlying technology
Digital Sequencing Platform: underlying technology Guardant Digital Sequencing Biochemistry and Error Reduction High-Efficiency Biochemistry Learning Bioinformatics Engine High- Learning 1000X reduction in Efficiency 2-3X conversion higher efficiency Bioinformatics sequencing error than other method
Slide 9: Liquid biopsy for therapy selection in advanced cancer
Liquid biopsy for therapy selection in advanced cancer Market leading Comprehensive Liquid Biopsy Guideline-complete clinical results for advanced >2MB footprint panel tailored for immuno- solid tumors in less than 7 days oncology and targeted therapy development 9
Slide 10: Guardant360 clinical data highlights
Guardant360 clinical data highlights 42 98 295 Clinical Peer-reviewed Scientific studies Publications abstracts 10
Slide 11: JAMA Oncology: Support for a blood first paradigm in NSCLC
JAMA Oncology: Support for a blood first paradigm in NSCLC University of Pennsylvania study of 323 NSCLC Patients tested with Guardant360 “These results [Aggarawal et al], combined with the patient 2x satisfaction with the relative ease 44% ~90% of providing blood rather than a solid tissue sample,
Slide 12: NILE: Guardant360 vs standard of care in 1st-line NSCLC
NILE: Guardant360 vs standard of care in 1st-line NSCLC Readout of primary endpoint expected in 1H 2019 300 NSCLC Patients Prospective, Multi-Center Trial Standard of Care Tissue Testing + Detection of NCCN Detection of NCCN Biomarkers with Tissue VS Biomarkers with Testing 12
Slide 13: Establishing a blood first paradigm in advanced cancer
Establishing a blood first paradigm in advanced cancer Guardant360 Pan-Cancer NILE FDA Approval Medicare Coverage Interim Readout PMA Submission Post FDA Approval via 1H 2019 1H 2019 the NGS NCD <7-day TAT 13
Slide 14: Medicare and strong private payer coverage today
Medicare and strong private payer coverage today and opportunity for increased coverage post FDA approval Q2 2016 Q3 2017 Q4 2017 Q1 2018 Q3 2018 Q4 2018 Total Covered 700K 3.7M 6.9M 21.9M 89.9M 115.3M Lives (Estimated) Estimates for Q2 2016 through Q4 2019 are as of 1/04/2019 14
Slide 15: Biopharma is a significant portion of $6B therapy selection market
Biopharma is a significant portion of $6B therapy selection market 1200+ targeted therapy and I-O programs 130,000+ patients ~$4 Billion Biopharmaceutical U.S. Market Opportunity Estimates ($mm) Clinical 50+ Opportunity ~$2 Billion $250 $2,120 pharma $320 Biopharmaceutical partners Opportunity $370
Slide 16: Partnership with AstraZeneca to develop plasma-based companion diagnostic tests
Partnership with AstraZeneca to develop multiple plasma- based companion diagnostic tests 16
Slide 17: AstraZeneca Partnership: more patients who may benefit from combination immunotherapy
AstraZeneca Partnership: Guardant found more patients who may benefit from combination immunotherapy Evaluable Patients for TMB analysis Guardant TMB High Overall Survival 809 460 Tissue TMBEvaluable TMB Patients Annals of Oncology, Volume 29, Issue suppl_10, 1 December 2018 17
Slide 18: Affordable multi-cancer assays for early detection and recurrence monitoring
To develop affordable multi-cancer assays for early detection and recurrence monitoring Lung CRC Breast Ovarian 18
Slide 19: Commercial engine as a significant R&D force multiplier
Commercial engine as a significant R&D force multiplier 80,000+ sample data & biobank Leveraging data, biobank and insights produced by commercial engine can create technology compounding effect - 1 19
Slide 20: The challenges of detecting residual disease using cell-free DNA
The challenges of detecting residual disease using cell-free DNA with high sensitivity and high specificity Detection Challenges Genomic Sensitivity Signatures • Genomic signatures alone max out at~50% sensitivity for early cancer TUMOR + Specificity • Non-tumor sources of biological noise, such as
Slide 21: Introducing the assay LUNAR
Introducing the assay LUNAR now available for research use by biopharmaceutical and academic researchers Genomic Alterations Biological Noise Filter LUNAR 80,000 ctDNA TEST RESULT Whole Signal Integration Genome ctDNA Sequencing Tests present / absent Epigenomic Epigenomic Signatures Classifier Laun
Slide 22: LUNAR Assay Performance
LUNAR Assay Performance Hybrid genomics and epigenomics approach can improve sensitivity to early stage cancers Late-stage • Assay reportable range down to 0.01% for genomic alterations • High quantitative correlation between genomic and epigenomic signal components • Epigenomic component detects Ge
Slide 23: Selecting patients with residual disease for adjuvant therapy may improve outcomes
- 1: Selecting patients with residual disease for adjuvant therapy may improve outcomes in multiple cancers Breast Lung CRC Ovarian e.g., Herceptin No well-defined standard for accurately Nearly 50% reduction selecting patients for adjuvant therapy in risk of recurrence(1) (1) N Engl J Med 2005;353:
Slide 24: Detection of post-op residual disease in CRC and NSCLC
- 1: Detection of post-op residual disease in CRC and NSCLC Study of colorectal cancer patients over 5 years Study of resected early-stage NSCLC • Prospective, comprehensive profiling 19.4 months follow-up • Retrospective surgical CRC study with 5 year follow-up Design • ctDNA assessment of MRD pre-
Slide 25: Addressing need for improved early cancer detection
- 2: Addressing need for improved early cancer detection Pilot data has demonstrated strong performance in early detection of lung cancer LUNAR-2 Lung Sensitivity by Stage Sensitivity Sensitivity at around 98% specificity STAGE 1 STAGE 2 Note: The pilot data presented here may be impacted by small s
Slide 26: Strong financial profile
Strong financial profile Revenues ($000’s) Sample Volumes (1) Gross Profit Margin (2) BioPharma Clinical 27,981 $57,766 49.3%49.3% +33% +100% +94% 20,960 20,644 $29,840 24.7%24.7% 17,304 7,337 3,656 2017 2018 2017 2018 2017 2018 Q3 YTD Q3 YTD Q3 YTD Q3 YTD Q3 YTD Q3 YTD (1) Clinical volume excludes
Slide 27: Significant opportunities to drive future growth
Significant opportunities to drive future growth -2 -1 International Increased expansion Continued adoption of COGS and CGP Blood-First opex Volume Growth leverage FDA approval Medicare NCD OMNI (pan-cancer) Commercial payer Pharma CDx reimbursement Medicare LCD tailwinds (lung) Near-term drivers Lo
Slide 28: Guardant
(@) GUARDANT
Guardant Health — Investor Presentation (January 2019) on 6ix